SCHEMBL22019720

SCHEMBL22019720

Cc1c2c(nc3c1CCC31CC1)CCC2

nearest known ligand 0.36

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.36
ACHE P22303 7/20 0.34
MEN1 O00255 1/20 0.34
MAPK1 P28482 1/20 0.34
KMT2A Q03164 1/20 0.34
BPTF Q12830 1/20 0.34
BCHE P06276 3/20 0.33
GRIN1 Q05586 3/20 0.33
GRIN2A Q12879 3/20 0.33
NOS3 P29474 1/20 0.33
NOS1 P29475 1/20 0.33
NOS2 P35228 1/20 0.33
NLRP3 Q96P20 1/20 0.33
CDC7 O00311 1/20 0.31
DBF4 Q9UBU7 1/20 0.31
ALDH1A1 P00352 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22019717 0.82 KDM4E (0.36) KDM4EACHEMEN1MAPK1KMT2A
SCHEMBL22019960 0.79 CYP1A2 (0.34) KDM4EACHEMEN1MAPK1KMT2A
SCHEMBL22020021 0.79 ACHE (0.57) KDM4EACHEMEN1MAPK1KMT2A
SCHEMBL30120743 0.79 ACHE (0.57) KDM4EACHEMEN1MAPK1KMT2A
SCHEMBL24872239 0.78 NLRP3 (0.35) KDM4EACHEMEN1MAPK1KMT2A
SCHEMBL22019939 0.78 USP2 (0.33) KDM4EACHEMEN1MAPK1KMT2A
SCHEMBL19272311 0.76 ACHE (0.54) KDM4EACHEMEN1MAPK1KMT2A
SCHEMBL22021457 0.74 NLRP3 (0.32) NLRP3
SCHEMBL22265389 0.74 NLRP3 (0.43) KDM4EACHEMEN1KMT2ANLRP3
SCHEMBL22021532 0.74 ACHE (0.58) KDM4EACHEMEN1MAPK1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020154499-A1 SULFONIMIDAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS INFLAMMASOME RESEARCH, INC. (US) 2020-07-30 WO disclosed
WO-2020102096-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS INFLAMMASOME RESEARCH, INC. (US) 2020-05-22 WO disclosed